ClinicalThought

Share

Program Content

Activities

  • EGFR TKI Combos
    Current Status of EGFR Tyrosine Kinase Inhibitor Combination Therapy in the Treatment of Newly Diagnosed EGFR-Mutated Advanced NSCLC
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 03, 2021

    Expires: December 02, 2022

  • Uncommon <i>EGFR</i> Mutations
    Management Strategies for Treating Patients With NSCLC and Uncommon EGFR Mutations
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: May 20, 2022

    Expires: May 19, 2023

  • Combos for EGFR Acquired Resistance
    Rational Combination Strategies in the Treatment of EGFR-Mutated NSCLC With Acquired Resistance to EGFR TKI Therapy: Updates From ASCO 2022
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 13, 2022

    Expires: July 12, 2023

  • Adjuvant Osimertinib
    My Thoughts Regarding Use of Adjuvant Osimertinib for Early-Stage EGFR Mutation–Positive NSCLC
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 24, 2022

    Expires: October 23, 2023

Faculty

cover img faculity

Edward B. Garon, MD, MS

Professor
Director of Thoracic Oncology
David Geffen School of Medicine at UCLA
Co-Director of Signal Transduction and Therapeutics Program
Jonsson Comprehensive Cancer Center at UCLA
Los Angeles, California

cover img faculity

Joel W. Neal, MD, PhD

Associate Professor of Medicine
Division of Oncology
Department of Medicine
Stanford University
Attending Physician
Stanford Cancer Institute
Palo Alto, California

cover img faculity

David Planchard, MD, PhD

Head of Thoracic Cancer Group
Department of Medical Oncology
Gustave Roussy
Villejuif, France

cover img faculity

Jonathan Riess, MD, MS

Associate Professor
Division of Hematology-Oncology
Department of Internal Medicine
UC Davis
Medical Director
Thoracic Oncology
UC Davis Comprehensive Cancer Center
Sacramento, California

Provided by

ProCE Banner

Supporters

Lilly